Company intelligence / Profile preview
Ionova Life Science
Shenzhen, Guangdong, Chinaionovabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Ionova Life Science is developing innovative anti-tumor and immuno-oncology therapies, with lead assets currently in Phase 1 clinical trials for advanced cancers including metastatic castration-resistant prostate cancer and advanced solid tumors. Early results are focused on safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugsMonoclonal antibodiesChemical drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Ionova Life Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ionova Life Science.